Psychometric Validation of the Growth Hormone Deficiency-Child Impact Measure (GHD-CIM)

Meryl Brod (), Michael Højby Rasmussen, Knud Vad, Suzanne Alolga, Donald M. Bushnell, Jacques Bedoin and Aristides Maniatis
Additional contact information
Meryl Brod: The Brod Group
Michael Højby Rasmussen: Novo Nordisk A/S
Knud Vad: Novo Nordisk A/S
Suzanne Alolga: The Brod Group
Donald M. Bushnell: Health Research Associates, Inc
Jacques Bedoin: Novo Nordisk A/S
Aristides Maniatis: Rocky Mountain Pediatric Endocrinology

PharmacoEconomics - Open, 2021, vol. 5, issue 3, No 14, 505-518

Abstract: Abstract Objective The aim of this study was to perform psychometric testing of the Growth Hormone Deficiency-Child Impact Measure (GHD-CIM): a patient-reported outcome (PRO) for children with GHD aged 9 to 0.70), as was test–retest reliability for the SWB, EWB and overall (above 0.70). At least one convergent validity hypotheses for each domain and overall was proven (r > 0.40). Known-groups validity hypotheses for the EWB and SWB domains were significant (p

Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-020-00252-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:5:y:2021:i:3:d:10.1007_s41669-020-00252-5

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-020-00252-5

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().